One dose versus two doses of COVID-19 vaccine for the prevention of breakthrough infections among people previously infected with SARS-Cov-2.

One dose versus two doses of COVID-19 vaccine for the prevention of breakthrough infections among people previously infected with SARS-Cov-2.

Publication date: Jan 01, 2024

Studies have suggested the effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 reinfection among those previously infected. However, it is not yet clear if one dose of the vaccine is enough to prevent breakthrough infections compared to two doses. Using data from Optum deidentified COVID-19 Electronic Health Record (EHR) data set, we assessed breakthrough infection risks in individuals previously infected, comparing those with one vaccine dose to those with two doses. Propensity scores were applied to mitigate confounding factors. Follow-up spanned 6 months, beginning 2 weeks postvaccination. Among 213‚ÄČ845 individuals, those receiving one vaccine dose had a significantly higher breakthrough infection risk than the two-dose group (HR 1. 69, 95% CI 1. 54-1. 85). This pattern was observed across genders, racial/ethnic groups, age categories, and vaccine types. This study reveals a substantial disparity in the risk of breakthrough infections between individuals receiving one versus two doses of the COVID-19 vaccine, suggesting that a single dose may not provide adequate protection against reinfection.

Concepts Keywords
Covid Breakthrough Infections
Months COVID-19
Postvaccination COVID-19
Racial COVID-19 Vaccines
Vaccine COVID-19 Vaccines
Female
Humans
infection
Male
Reinfection
SARS-CoV-2
SARS-CoV-2
vaccine

Semantics

Type Source Name
disease VO dose
disease VO COVID-19 vaccine
disease MESH breakthrough infections
disease VO effectiveness
disease MESH COVID-19
disease MESH reinfection
disease VO vaccine
disease VO data set
disease VO vaccine dose
disease MESH Breakthrough Infections COVID-19
disease MESH infection

Original Article

(Visited 1 times, 1 visits today)